A fundamental issue in molecular pharmacology is to define how agonist-receptor interaction differs from that of antagonist-receptor interaction. The V 1a vasopressin receptor (V 1a R) is a member of a family of related G-protein-coupled receptors (GPCRs) that are activated by vasopressin, oxytocin (OT) and related peptides. A segment of the N-terminus that was required for agonist binding, but not antagonist binding, was identified by characterizing truncated V 1a R constructs. Site-directed mutagenesis revealed that a single residue ( 
Introduction
G-protein-coupled receptors (GPCRs) are a large family of structurally related proteins that mediate their effects by coupling to G-proteins. Several hundred GPCRs have now been cloned. Despite being activated by a wide variety of stimuli, from photons to glycoproteins, these receptors exhibit primary sequence identity and a conserved tertiary structure that comprises a bundle of seven transmembrane domains [1] . Analysis of these sequences has revealed that GPCRs can be further categorized into the rhodopsin/ β-adrenergic receptor family, the secretin receptor family and the metabotropic glutamate receptor family [2] [3] [4] . The largest and most extensively characterized of these is the rhodopsin/β-adrenergic receptor family [5] .
The neurohypophysial hormones [arginine 8 ]vasopressin (AVP) and oxytocin (OT) are structurally homologous. Both are nonapeptides, they possess an intramolecular disulphide bond and their sequences differ at just two positions. Nevertheless, these neuropeptides have discrete physiological roles. AVP exhibits a plethora of responses in addition to the well-characterized vasopressor and antidiuretic actions [6] , while OT stimulates uterine contraction at parturition and promotes lactation [7] . The physiological effects of both of these hormones are mediated by receptors that belong to the rhodopsin/β-adrenergic receptor family. Four different receptor subtypes have been defined and cloned. The V 1a vasopressin receptor (V 1a R), the V 1b vasopressin receptor (V 1b R) and the OT receptor (OTR) stimulate phosphoinositidase C, whereas the V 2 vasopressin receptor (V 2 R) stimulates adenylate cyclase [8, 9] . V 1a R is widely distributed and mediates nearly all of the actions of AVP with the notable exceptions of antidiuresis (V 2 R) and corticotropin secretion (V 1b R). All four receptor subtypes exhibit different, but related, pharmacological profiles [10] . In addition to overlapping ligand-binding characteristics, these receptors share certain sequence motifs which identify these receptors as a sub-family of GPCRs [11, 12] . The neurohypophysial peptide hormone family of GPCRs also includes the receptors for vasotocin, mesotocin and isotocin, which are evolutionary precursors of AVP and OT [13] .
Agonist binding to GPCRs
The primary event in the activation of a receptor by a hormone or a neurotransmitter is the binding of the natural agonist to its receptor. This initiates a plethora of postbinding events, which include second messenger generation, receptor phosphorylation, changes in receptor palmitoylation and desensitization [14] . The use of synthetic analogues to mimic this event (agonists), or to prevent its occurrence (antagonists), is of fundamental importance to a wide range of therapeutic strategies. For this reason, the identification of the ligand-binding site in GPCRs has been the subject of extensive research over the last few years [2, 15] . Although the binding of agonists and antagonists to the receptor is usually competitive, there is obviously a critical difference in that occupancy by agonists generates an intracellular signal, whereas the binding of antagonists does not. Defining the differences at the molecular level between the receptor-agonist complex and receptor-antagonist complex is central to our understanding of GPCR activation and to the rational design of receptorspecific agonists and antagonists.
For small biogenic amines, such as acetylcholine (ACh) and noradrenaline, the binding site is located in the hydrophobic core created by the receptor's transmembrane helical bundle. Evidence for this was provided by mutagenesis [16] , micro-sequencing of affinity-labelled receptors [17] and the use of fluorescent ligands [18] . Peptide ligands are generally far larger than catecholamines and size considerations alone dictate that the binding site for these ligands may incorporate extracellular domains. This has been shown to be the case for several peptide receptors including the neurokinin-1 NK 1 receptor [19] , the angiotensin AT 1 receptor [20] , the neuropeptide Y1 receptor [21] and the endothelin ET A receptor [22] . Indeed, for the large glycoprotein hormones such as luteinizing hormone, the markedly extended N-terminal domain alone is sufficient for high-affinity binding [23] .
Agonist binding to neurohypophysial peptide hormone receptors
The V 1a R is particularly useful for studying agonist binding to GPCRs for peptide hormones as an extensive range of potent and well-characterized ligands is available for probing the binding site [10] . These ligands can be characterized into four different classes: (i) peptide agonists; (ii) cyclic peptide antagonists possessing a disulphide bond, a 20-membered ring and a short peptide tail; (iii) linear peptide antagonists; and (iv) non-peptide antagonists. In addition, the V 1a R and the OTR are homologous and possess related, but discrete, pharmacology which has resulted in the development of a series of agonists with different V 1a R/OTR selectivities. This makes it possible not only to investigate agonist-receptor binding, but also agonist selectivity.
A combination of mutagenesis and molecular modelling concluded that the binding site for AVP was completely buried in a 15-20 A a deep cleft that is contained within the transmembrane helical bundle of the V 1a R [24] . However, the extracellular face of the V 1a R has also been implicated in the ligand-binding platform as both peptide mimetic studies [25] and photoaffinity labelling [26] have implicated the first extracellular loop of AVP receptors in ligand recognition. In addition, a single residue in this loop (Tyr 115 in the V 1a R and the corresponding locus Asp 103 in the V 2 R) has been shown to have a role in agonist selectivity [27, 28] .
Role of the N-terminus of V 1a R in ligand recognition
The largest single component of the extracellular face of the V 1a R is the N-terminus. This domain is composed of 48 amino acid residues and it is N-glycosylated at two positions, Asn 14 and Asn 27 [29, 30] . To address the role of the N-terminal domain of the V 1a R in ligand recognition, a series of receptor constructs was made with progressively greater N-terminal deletions. Initially, three mutant receptors, [ 
were engineered (the numbering refers to the inclusive range of amino acid residues that was deleted). The pharmacological characteristics of the truncated receptor constructs were investigated and compared with wild-type receptors following expression in HEK-293T cells [31] . The wild-type receptor and truncated constructs were all expressed at the same level of approx. 1-2 pmol/mg of protein, indicating that no essential information for the assembly of functional V 1a Rs is provided by the N-terminal sequence. In addition, oligosaccharide modification does not have a role in ligand recognition, or receptor folding, as the [ 2-36]-V 1a R construct exhibited wild-type pharmacology despite lacking both of these glycosylation sites. This conclusion has been corroborated by a separate study in which we substituted both of these asparagine residues using sitedirected mutagenesis [29] ; however, further truncations of the N-terminus to Asn 47 ([ 2-47]V 1a R) resulted in a profound decrease in agonist affinity, with the K d for AVP increasing approx. 2000-fold. In marked contrast, the affinity of the three antagonists for the [ 2-47]V 1a R was not markedly different from wild-type. This retention of high-affinity antagonistbinding by the truncated V 1a R constructs was important practically, as it allowed the altered binding characteristics of agonists to be determined quantitatively using the antagonist 
Is functional rescue of [∆2-47]V 1a R possible using the N-terminus of the V 1a R or the OTR?
The use of relatively small synthetic peptides that correspond to sequences within receptors has proven to be a useful strategy for establishing the functional importance of individual domains. Such peptides can sometimes mimic a property of the whole receptor, such as ligand binding [32] or G-protein activation [33] . We synthesized the peptide GSNGSQEAARLGEGDSPLGDVRN (equivalent to residues 25-47), which incorporates the sub-domain in the N-terminus required for agonist binding; however, the synthetic peptide mimetic (at a concentration of 10 µM) did not recover high-affinity binding of AVP.
It was reasoned that a molecularly dispersed peptide in three-dimensional space may not be as effective as one that had been orientated in the same plane as the V 1a R construct. To ensure that the N-terminus was tethered appropriately to the membrane, we engineered the construct [1-86]V 1a R, which incorporates the wild-type V 1a R N-terminus, the first transmembrane domain (TM1) and most of the first intracellular loop. However, [1-86]V 1a R alone did not bind AVP and did not recover high-affinity AVP-binding when co-expressed with [ 2-47]V 1a R. Consequently, the Nterminal subdomain has to be contiguous with the receptor polypeptide chain to fulfil its role in high-affinity agonistbinding. It could not function as a discrete, independently folded, supplementary domain.
V 1a R and OTR exhibit related pharmacological profiles with many agonists and antagonists (peptide and nonpeptide) binding to both receptors [10, 34] . Indeed, AVP itself is a high-affinity agonist at both receptors. Agonists that display selectivity for V 1a R or OTR have nevertheless been developed [35, 36] . The N-terminus of OTRs from different species is some 12 residues shorter than that of the corresponding V 1a R. Moreover, with the exception of the juxtamembrane region, there is no sequence identity between the N-terminus of V 1a Rs and OTRs. Sequence identity is apparent however, within each receptor subtype. It is therefore possible that this N-terminal subdomain not only allows agonists to bind, but also contributes to agonist selectivity. To investigate this, a chimaeric receptor (OTR N -V 1a R) was constructed in which the N-terminus domain of the V 1a R was replaced by the corresponding OTR sequence [31] . The affinity of AVP for this OTR N -V 1a R chimaera (K d = 7.5 nM) was increased by 240-fold compared with its affinity for V 1a R, and was only slightly less than the affinity for wild-type V 1a R (K d = 1.0 nM). The pharmacological profile of the OTR N -V 1a R chimaera was essentially the same as that of wild-type V 1a R. The AVP doseresponse curve of the OTR N -V 1a R chimaera was slightly to the right of the wild-type V 1a R (EC 50 = 1.8 nM and 0.4 nM respectively), consistent with the slightly lower affinity of AVP for this construct. Overall, the pattern of signalling of OTR N -V 1a R was typical of a wild-type V 1a R, indicating that the N-terminus is not the molecular discriminator for OTR/V 1a R-selective agonists.
Defining individual residues within the N-terminus that provide the agonistbinding epitope(s)
Engineering further truncated V 1a R constructs ([ 2-41]V 1a R and [ 2-44]V 1a R) in conjunction with alanine-scanning mutagenesis of residues Leu 42 -Asn 47 inclusive (Figure 1 ), revealed that there was a major and a minor contributor to high-affinity agonist-binding in the N-terminal domain. The minor component was provided by a 'patch' of three residues (Leu 42 , Gly 43 and Asp 44 ) acting in concert. The major component was provided by a single residue, Arg 46 [37] . Consequently, the affinity of AVP for the mutated [R46A]V 1a R was similar to that of V 1a R (K d = 1300 nM and 1800 nM, respectively). The decrease in affinity for [R46A]V 1a R was restricted to agonists however, as all the classes of antagonist exhibited wild-type affinity.
[R46A]V 1a R had disrupted second messenger generation, with the EC 50 with AVP-induced InsP-InsP 3 production increasing 65-fold compared with wild-type V 1a R. This contrasts with V 1a R, which did not couple even when challenged with 10 µM AVP. This suggests that the conformational context of the N-terminus surrounding Arg 46 was also important for receptor activation. The N-terminus of other GPCRs with peptide ligands has been shown to provide agonist-binding contacts, including the angiotensin AT 1 receptor [20] and the neurokinin NK 1 receptor [19] . This is not a universal situation, as there is no role for the N-terminus for ligands binding to the melanocortin receptor [38] . In contrast, this domain of the κ-opiate receptor is required for antagonist binding, but not agonist binding [39] .
A conserved role for arginine in the N-terminus of members of the neurohypophysial peptide hormone receptors GPCR family?
A sequence alignment of members of neurohypophysial peptide hormone receptors cloned to date from different species revealed that an arginine residue is conserved at the locus corresponding to Arg 46 in the N-terminus of the V 1a R. This suggested a possible conservation of function throughout this subfamily. Indeed, the N-terminus of the vasotocin receptor is required for vasotocin binding [40] . Support for this hypothesis came from characterizing OTR constructs with progressively greater N-terminal deletions. This revealed that there was a subdomain specifically required for high-affinity agonist-binding in a similar manner to that cited for the V 1a R [41] . Furthermore, mutation of Arg 34 (which corresponds to Arg 46 of the rat V 1a R) disrupted agonist binding and intracellular signalling, but did not perturb antagonist binding (peptide and non-peptide) [42] .
The Transmembrane helices of the V 1a R are shown as cylinders traversing the lipid bilayer (in grey). Experimentally-determined glycosylation sites [29] are indicated by branched structures. Palmitoylation of a C-terminal cysteine couplet at the end of helix VIII is illustrated as a 'zig-zag' [14] . The insert shows the location of some V 1a R truncations referred to in the text. The numbers indicate the receptor residues deleted in each construct. The residue critical for high-affinity agonist-binding, Arg 46 , is highlighted.
or reversing the charge at this locus ([R46E]V 1a R). In each case, the affinity of AVP was reduced by approx. 1400-fold compared with wild-type V 1a R. In contrast, the binding affinities of the three different antagonists were unchanged. Furthermore, none of the substituted residues could support wild-type intracellular signalling. Consequently, there is an absolute requirement for arginine at this locus. The importance of this Arg 46 to ligand binding may be a direct contact between receptor and agonist, but it does not necessarily have to be so. Equally plausible is an indirect effect of the N-terminus, in which the guanidinium group of the arginine residue interacts with juxtaposed extracellular loops to constrain or orientate them into a conformation with high affinity for agonists. This could involve Arg 46 interacting with negatively charged residues. It is noteworthy in this regard that a number of charged residues in the extracellular loops of the V 1a R are conserved throughout the neurohypophysial peptide hormone receptor family.
Concluding remarks
The N-terminus of the V 1a R contains an arginine residue which is critical for high-affinity agonist binding, but has no role in antagonist binding. Furthermore, this residue is conserved throughout the family of neurohypophysial peptide hormone receptors, which suggests a conservation of function. For one of these receptors, OTR, this was established experimentally. The molecular basis for the importance of this arginine is poorly defined as yet, but may involve intra-molecular contacts, possibly with negatively charged residues.
The importance of extracellular domains for ligand recognition and receptor activation has been reported for several peptide hormones in addition to AVP and OT [19, 20, [40] [41] [42] . However, insight gained for peptide receptors may also be relevant to biogenic amine receptors. Although it is well documented that the binding site for ACh and noradrenaline are within the helical bundle [2, 15, 43] , mutation of extracellular residues can change amine receptor function. For example, nocturnal asthma has been associated with the enhanced down-regulation exhibited by the Gly 16 β 2 -adrenergic receptor polymorphism, relative to the Arg 16 polymorphism [44] . In addition, the exofacial TM3 domain of the muscarinic ACh receptor together with residues in TM4 have been proposed to contribute to a peripheral ligandbinding site for ACh [45, 46] . This site would act as an initial contact site prior to ACh entering the central binding site. Furthermore, an 'ectopic' binding site has been reported for the M 1 muscarinic ACh receptor [47] . It is becoming increasingly apparent that when it comes to ligand binding, GPCRs are multifaceted.
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